Samimi G - Search Results

1

Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.

Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB. Samimi G, et al. Clin Cancer Res. 2000 Apr;6(4):1415-21. Clin Cancer Res. 2000. PMID: 10778972

2

Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.

Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Samimi G, et al. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5853-9. Clin Cancer Res. 2003. PMID: 14676106

3

Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.

Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M, Howell SB. Katano K, et al. Among authors: samimi g. Clin Cancer Res. 2004 Jul 1;10(13):4578-88. doi: 10.1158/1078-0432.CCR-03-0689. Clin Cancer Res. 2004. PMID: 15240550

4

Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.

Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. Samimi G, et al. Clin Cancer Res. 2004 Jul 15;10(14):4661-9. doi: 10.1158/1078-0432.CCR-04-0137. Clin Cancer Res. 2004. PMID: 15269138

5

Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.

Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB. Safaei R, et al. Among authors: samimi g. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):756-67. Clin Cancer Res. 2005. PMID: 15701866

6

Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.

Samimi G, Howell SB. Samimi G, et al. Cancer Chemother Pharmacol. 2006 Jun;57(6):781-8. doi: 10.1007/s00280-005-0121-5. Epub 2005 Sep 17. Cancer Chemother Pharmacol. 2006. PMID: 16170571

7

Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.

Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. Cheng TC, et al. Among authors: samimi g. Cancer Chemother Pharmacol. 2006 Sep;58(3):384-95. doi: 10.1007/s00280-005-0171-8. Epub 2006 Jan 11. Cancer Chemother Pharmacol. 2006. PMID: 16404635

8

Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.

Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB. Samimi G, et al. Cancer Chemother Pharmacol. 2007 Feb;59(3):301-12. doi: 10.1007/s00280-006-0271-0. Epub 2006 Jun 13. Cancer Chemother Pharmacol. 2007. PMID: 16770583

9

Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.

Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Katano K, et al. Among authors: samimi g. Cancer Res. 2002 Nov 15;62(22):6559-65. Cancer Res. 2002. PMID: 12438251

10

The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.

Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. Katano K, et al. Among authors: samimi g. Mol Pharmacol. 2003 Aug;64(2):466-73. doi: 10.1124/mol.64.2.466. Mol Pharmacol. 2003. PMID: 12869652

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters